Autobio Diagnostics Co Ltd
Autobio Diagnostics Co., Ltd. engages in the research and development, production, marketing, sale, and service of clinical diagnostic products in China and internationally. The company offers immunoassay, biochemistry, and microbiology products; reagents and instruments; and technical and support, and training services, as well as engages in biology research and development activities. Its immun… Read more
Autobio Diagnostics Co Ltd (603658) - Net Assets
Latest net assets as of September 2025: CN¥8.85 Billion CNY
Based on the latest financial reports, Autobio Diagnostics Co Ltd (603658) has net assets worth CN¥8.85 Billion CNY as of September 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (CN¥11.73 Billion) and total liabilities (CN¥2.88 Billion). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | CN¥8.85 Billion |
| % of Total Assets | 75.43% |
| Annual Growth Rate | 36.17% |
| 5-Year Change | 31.99% |
| 10-Year Change | 1109.63% |
| Growth Volatility | 45.12 |
Autobio Diagnostics Co Ltd - Net Assets Trend (2011–2024)
This chart illustrates how Autobio Diagnostics Co Ltd's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Autobio Diagnostics Co Ltd (2011–2024)
The table below shows the annual net assets of Autobio Diagnostics Co Ltd from 2011 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | CN¥8.69 Billion | +0.29% |
| 2023-12-31 | CN¥8.67 Billion | +9.53% |
| 2022-12-31 | CN¥7.91 Billion | +6.88% |
| 2021-12-31 | CN¥7.40 Billion | +12.42% |
| 2020-12-31 | CN¥6.59 Billion | +149.96% |
| 2019-12-31 | CN¥2.63 Billion | +34.01% |
| 2018-12-31 | CN¥1.97 Billion | +16.36% |
| 2017-12-31 | CN¥1.69 Billion | +2.71% |
| 2016-12-31 | CN¥1.64 Billion | +128.92% |
| 2015-12-31 | CN¥718.55 Million | +43.44% |
| 2014-12-31 | CN¥500.94 Million | +47.15% |
| 2013-12-31 | CN¥340.42 Million | +45.58% |
| 2012-12-31 | CN¥233.84 Million | +48.98% |
| 2011-12-31 | CN¥156.96 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Autobio Diagnostics Co Ltd's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 3809.6% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | CN¥4.38 Billion | 50.87% |
| Common Stock | CN¥581.01 Million | 6.74% |
| Other Comprehensive Income | CN¥296.64 Million | 3.44% |
| Other Components | CN¥3.36 Billion | 38.94% |
| Total Equity | CN¥8.62 Billion | 100.00% |
Autobio Diagnostics Co Ltd Competitors by Market Cap
The table below lists competitors of Autobio Diagnostics Co Ltd ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Electricity Gnrtng NVtg
OTCGREY:EYUUF
|
$778.73 Million |
|
NOLATO AB SER.B
F:NBF
|
$778.95 Million |
|
ADDNODE GROUP AB SK 3
F:AR7
|
$779.20 Million |
|
Wanbangde Pharmaceutical Holding Group Co Ltd
SHE:002082
|
$779.24 Million |
|
Qurient Co. Ltd
KQ:115180
|
$778.59 Million |
|
PATTIES FOODS - Frankfurt Stock Exchang
F:PH4
|
$777.98 Million |
|
Nano Nuclear Energy Inc. Common Stock
NASDAQ:NNE
|
$777.85 Million |
|
CT Real Estate Investment Trust
PINK:CTRRF
|
$777.74 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Autobio Diagnostics Co Ltd's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 8,535,461,518 to 8,616,530,318, a change of 81,068,800 (0.9%).
- Net income of 1,194,451,909 contributed positively to equity growth.
- Dividend payments of 623,380,254 reduced retained earnings.
- Share repurchases of 566,061,000 reduced equity.
- Other comprehensive income increased equity by 106,411.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | CN¥1.19 Billion | +13.86% |
| Dividends Paid | CN¥623.38 Million | -7.23% |
| Share Repurchases | CN¥566.06 Million | -6.57% |
| Other Comprehensive Income | CN¥106.41K | +0.0% |
| Other Changes | CN¥75.95 Million | +0.88% |
| Total Change | CN¥- | 0.95% |
Book Value vs Market Value Analysis
This analysis compares Autobio Diagnostics Co Ltd's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 2.33x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
- The price-to-book ratio has decreased from 130.13x to 2.33x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2011-12-31 | CN¥0.27 | CN¥34.84 | x |
| 2012-12-31 | CN¥0.47 | CN¥34.84 | x |
| 2013-12-31 | CN¥0.70 | CN¥34.84 | x |
| 2014-12-31 | CN¥1.02 | CN¥34.84 | x |
| 2015-12-31 | CN¥1.47 | CN¥34.84 | x |
| 2016-12-31 | CN¥3.22 | CN¥34.84 | x |
| 2017-12-31 | CN¥3.04 | CN¥34.84 | x |
| 2018-12-31 | CN¥3.53 | CN¥34.84 | x |
| 2019-12-31 | CN¥4.68 | CN¥34.84 | x |
| 2020-12-31 | CN¥11.61 | CN¥34.84 | x |
| 2021-12-31 | CN¥12.41 | CN¥34.84 | x |
| 2022-12-31 | CN¥13.33 | CN¥34.84 | x |
| 2023-12-31 | CN¥14.72 | CN¥34.84 | x |
| 2024-12-31 | CN¥14.93 | CN¥34.84 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Autobio Diagnostics Co Ltd utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 13.86%
- The company shows good efficiency in utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 26.71%
- • Asset Turnover: 0.38x
- • Equity Multiplier: 1.38x
- Recent ROE (13.86%) is below the historical average (26.59%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2011 | 38.96% | 28.87% | 1.08x | 1.25x | CN¥45.46 Million |
| 2012 | 41.11% | 30.21% | 1.14x | 1.20x | CN¥72.74 Million |
| 2013 | 36.45% | 30.31% | 1.00x | 1.21x | CN¥90.03 Million |
| 2014 | 41.57% | 36.96% | 0.86x | 1.30x | CN¥158.13 Million |
| 2015 | 38.69% | 38.80% | 0.76x | 1.32x | CN¥206.17 Million |
| 2016 | 21.26% | 35.68% | 0.54x | 1.11x | CN¥185.27 Million |
| 2017 | 26.78% | 31.89% | 0.64x | 1.31x | CN¥279.84 Million |
| 2018 | 29.17% | 29.15% | 0.73x | 1.38x | CN¥369.71 Million |
| 2019 | 30.28% | 28.89% | 0.63x | 1.66x | CN¥518.47 Million |
| 2020 | 11.54% | 25.11% | 0.37x | 1.26x | CN¥100.06 Million |
| 2021 | 13.38% | 25.85% | 0.41x | 1.27x | CN¥245.99 Million |
| 2022 | 15.00% | 26.28% | 0.42x | 1.35x | CN¥389.18 Million |
| 2023 | 14.26% | 27.40% | 0.38x | 1.35x | CN¥363.89 Million |
| 2024 | 13.86% | 26.71% | 0.38x | 1.38x | CN¥332.80 Million |
Industry Comparison
This section compares Autobio Diagnostics Co Ltd's net assets metrics with peer companies in the Medical Devices industry.
Industry Context
- Industry: Medical Devices
- Average net assets among peers: $1,879,733,462
- Average return on equity (ROE) among peers: 24.67%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Autobio Diagnostics Co Ltd (603658) | CN¥8.85 Billion | 38.96% | 0.33x | $778.70 Million |
| Shanghai Kehua Bio-Engineering Co Ltd (002022) | $792.82 Million | 25.77% | 0.17x | $318.98 Million |
| Jiangsu Yuyue Medical Equipment & Supply Co Ltd (002223) | $482.51 Million | 20.84% | 0.32x | $2.79 Billion |
| Double Medical Technology Inc (002901) | $224.61 Million | 43.10% | 0.32x | $404.40 Million |
| Wuhan Easy Diagnosis Biomedicine Co Ltd Class A (002932) | $1.42 Million | 98.49% | 2.27x | $281.14 Million |
| Lepu Medical Tech Beijing (300003) | $12.27 Billion | 14.01% | 0.69x | $2.71 Billion |
| INKON Life Technology Co Ltd (300143) | $1.81 Billion | -20.17% | 0.37x | $637.77 Million |
| Edan Instruments Inc (300206) | $1.26 Billion | 7.37% | 0.15x | $501.55 Million |
| Guangdong Biolight Meditech Co Ltd (300246) | $504.27 Million | 13.31% | 0.36x | $360.97 Million |
| Beijing Leadman Biochemistry Co Ltd (300289) | $1.44 Billion | 2.82% | 0.20x | $267.10 Million |
| Sinocare Inc (300298) | $17.42 Million | 41.15% | 0.68x | $952.60 Million |